1
|
Böttger F, Radonic T, Bahce I, Monkhorst K, Piersma SR, Pham TV, Dingemans AC, Hillen LM, Santarpia M, Giovannetti E, Smit EF, Burgers SA, Jimenez CR. Identification of protein biomarkers for prediction of response to platinum-based treatment regimens in patients with non-small cell lung cancer. Mol Oncol 2024; 18:1417-1436. [PMID: 38010703 PMCID: PMC11161729 DOI: 10.1002/1878-0261.13555] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/03/2023] [Revised: 11/06/2023] [Accepted: 11/21/2023] [Indexed: 11/29/2023] Open
Abstract
The majority of patients with resected stage II-IIIA non-small cell lung cancer (NSCLC) are treated with platinum-based adjuvant chemotherapy (ACT) in a one-size-fits-all approach. However, a significant number of patients do not derive clinical benefit, and no predictive patient selection biomarker is currently available. Using mass spectrometry-based proteomics, we have profiled tumour resection material of 2 independent, multi-centre cohorts of in total 67 patients with NSCLC who underwent ACT. Unsupervised cluster analysis of both cohorts revealed a poor response/survival sub-cluster composed of ~ 25% of the patients, that displayed a strong epithelial-mesenchymal transition signature and stromal phenotype. Beyond this stromal sub-population, we identified and validated platinum response prediction biomarker candidates involved in pathways relevant to the mechanism of action of platinum drugs, such as DNA damage repair, as well as less anticipated processes such as those related to the regulation of actin cytoskeleton. Integration with pre-clinical proteomics data supported a role for several of these candidate proteins in platinum response prediction. Validation of one of the candidates (HMGB1) in a third independent patient cohort using immunohistochemistry highlights the potential of translating these proteomics results to clinical practice.
Collapse
Affiliation(s)
- Franziska Böttger
- Department of Medical Oncology, Cancer Center AmsterdamAmsterdam UMC – location VUmcThe Netherlands
- OncoProteomics Laboratory, Cancer Center AmsterdamAmsterdam UMC – location VUmcThe Netherlands
| | - Teodora Radonic
- Department of PathologyAmsterdam UMC – location VUmcThe Netherlands
| | - Idris Bahce
- Department of Pulmonary DiseasesAmsterdam UMC – location VUmcThe Netherlands
| | - Kim Monkhorst
- Division of PathologyThe Netherlands Cancer Institute – Antoni van Leeuwenhoek HospitalAmsterdamThe Netherlands
| | - Sander R. Piersma
- Department of Medical Oncology, Cancer Center AmsterdamAmsterdam UMC – location VUmcThe Netherlands
- OncoProteomics Laboratory, Cancer Center AmsterdamAmsterdam UMC – location VUmcThe Netherlands
| | - Thang V. Pham
- Department of Medical Oncology, Cancer Center AmsterdamAmsterdam UMC – location VUmcThe Netherlands
- OncoProteomics Laboratory, Cancer Center AmsterdamAmsterdam UMC – location VUmcThe Netherlands
| | - Anne‐Marie C. Dingemans
- Department of Pulmonary Diseases, GROW School for Oncology & Developmental BiologyMaastricht University Medical CenterThe Netherlands
- Department of Pulmonary DiseasesErasmus Medical CentreRotterdamThe Netherlands
| | - Lisa M. Hillen
- Department of PathologyMaastricht University Medical CenterThe Netherlands
| | - Mariacarmela Santarpia
- Medical Oncology Unit, Department of Human Pathology “G. Barresi”University of MessinaItaly
| | - Elisa Giovannetti
- Department of Medical Oncology, Cancer Center AmsterdamAmsterdam UMC – location VUmcThe Netherlands
- Cancer Pharmacology LabFondazione Pisana per la ScienzaPisaItaly
| | - Egbert F. Smit
- Division of Thoracic OncologyThe Netherlands Cancer Institute – Antoni van Leeuwenhoek HospitalAmsterdamThe Netherlands
- Department of Pulmonary DiseasesLeiden University Medical CenterThe Netherlands
| | - Sjaak A. Burgers
- Division of Thoracic OncologyThe Netherlands Cancer Institute – Antoni van Leeuwenhoek HospitalAmsterdamThe Netherlands
| | - Connie R. Jimenez
- Department of Medical Oncology, Cancer Center AmsterdamAmsterdam UMC – location VUmcThe Netherlands
- OncoProteomics Laboratory, Cancer Center AmsterdamAmsterdam UMC – location VUmcThe Netherlands
| |
Collapse
|
2
|
Dhengale SD, Rode CV, Kolekar GB, Anbhule PV. Synthesis of indeno-[1,2- b]-quinoline-9,11(6 H,10 H)-dione and 7,7-dimethyl-10-aryl-7,8-dihydro-5 H-indeno[1,2- b]quinoline-9,11(6 H,10 H)-dione derivatives in presence of heterogeneous Cu/zeolite-Y as a catalyst. RSC Adv 2022; 12:2083-2093. [PMID: 35425268 PMCID: PMC8979121 DOI: 10.1039/d1ra06637d] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/03/2021] [Accepted: 11/30/2021] [Indexed: 12/19/2022] Open
Abstract
A simple method for the synthesis of indeno-[1,2-b]-quinoline-9,11-(6H,10H)-dione derivatives and 7,7-dimethyl-10-aryl-7,8-dihydro-5H-indeno[1,2-b]quinoline-9,11(6H,10H)-diones through the reaction of aromatic aldehydes, indan-1,3-dione, dimedone, and p-toluidine/ammonium acetate in the presence of heterogeneous CuO supported on a zeolite-Y catalyst has been investigated in ethanol under reflux conditions. By this method, the reaction time has been reduced, giving an excellent yield of the product. The catalyst was prepared by a hydrothermal method followed by a wet impregnation method. The catalyst had shown Brønsted acid sites and Lewis acid sites. The used catalyst could be actively recycled with a marginal decrease in yield up to five recycles. The prepared catalyst was characterized by FT-IR, pyridine FT-IR, XRD, SEM, EDS, XPS, TEM, and BET surface area analysis. The synthesized compounds were characterized by FT-IR, 1H NMR, 13C NMR and GC-MS spectroscopy.
Collapse
Affiliation(s)
- Shankar D Dhengale
- Medicinal Chemistry Research Laboratory, Department of Chemistry, Shivaji University Kolhapur-416004 India
- Chemical Engineering and Process Development Division, CSIR-National Chemical Laboratory Dr Homi Bhabha Road Pune-411008 India
| | - Chandrashekhar V Rode
- Chemical Engineering and Process Development Division, CSIR-National Chemical Laboratory Dr Homi Bhabha Road Pune-411008 India
| | - Govind B Kolekar
- Fluorescence Spectroscopy Research Laboratory, Department of Chemistry, Shivaji University Kolhapur-416004 MS India
| | - Prashant V Anbhule
- Medicinal Chemistry Research Laboratory, Department of Chemistry, Shivaji University Kolhapur-416004 India
| |
Collapse
|
3
|
Fathi M, Naimi-Jamal MR, Dekamin MG, Panahi L, Demchuk OM. A straightforward, environmentally beneficial synthesis of spiro[diindeno[1,2-b:2',1'-e]pyridine-11,3'-indoline]-2',10,12-triones mediated by a nano-ordered reusable catalyst. Sci Rep 2021; 11:4820. [PMID: 33649384 PMCID: PMC7921678 DOI: 10.1038/s41598-021-84209-6] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/20/2020] [Accepted: 02/15/2021] [Indexed: 11/09/2022] Open
Abstract
A library of new spiro[diindeno[1,2-b:2',1'-e]pyridine-11,3'-indoline]-2',10,12-trione derivatives has been prepared in an efficient, one-pot pseudo four-component method mediated by a reusable heterogeneous nano-ordered mesoporous SO3H functionalized-silica (MCM-41-SO3H) catalyst. Excellent yields, short reaction times, as well as convenient non-chromatographic purification of the products and environmental benefits such as green and metal-free conditions constitute the main advantages of the developed synthetic methodology. The obtained fused indole-indenone dyes would be of interest to pharmaceutical and medicinal chemistry. Furthermore, due to their sensitivity to pH changes, they could be used as novel pH indicators.
Collapse
Affiliation(s)
- Mahsa Fathi
- Research Laboratory of Green Organic Synthesis and Polymers, Department of Chemistry, Iran University of Science and Technology, Tehran, 16846-13114, Islamic Republic of Iran
| | - M Reza Naimi-Jamal
- Research Laboratory of Green Organic Synthesis and Polymers, Department of Chemistry, Iran University of Science and Technology, Tehran, 16846-13114, Islamic Republic of Iran.
| | - Mohammad G Dekamin
- Research Laboratory of Green Organic Synthesis and Polymers, Department of Chemistry, Iran University of Science and Technology, Tehran, 16846-13114, Islamic Republic of Iran
| | - Leila Panahi
- Research Laboratory of Green Organic Synthesis and Polymers, Department of Chemistry, Iran University of Science and Technology, Tehran, 16846-13114, Islamic Republic of Iran
| | - Oleg M Demchuk
- Pharmaceutical Research Institute, 8 Rydygiera Street, 01-793, Warsaw, Poland
| |
Collapse
|
4
|
van Gijn R, Lendfers RRH, Schellens JHM, Bult A, Beijnen JH. Dual topoisomerase I/II inhibitors. J Oncol Pharm Pract 2016. [DOI: 10.1177/107815520000600303] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Topoisomerase (topo) I and II are nuclear enzymes, which play a major role in the topological rearrangement of DNA during replication and transcription processes. In the course of years, many different agents have been found which can inhibit the topos and thereby exploit cytotoxicity, also against tumour cells. Selective inhibition of the topo I enzyme can, however, induce a reactive increase in topo II levels, and vice versa. This mechanism is associated with the development of drug resistance. Dual inhibition of both topo I and II may, theoretically, overcome this resistance problem. In this review, the most important and promising dual topo I/II inhibitors designed as anticancer agents will be discussed. Thus far, only the indolyl quinoline derivative TAS-103, the 7 H-benzo [ e] pyrido [4,3- b] indole derivative intoplicine, and the acridine derivative PZA have been shown to be dual topo inhibitors with high cytotoxicity.
Collapse
Affiliation(s)
- R van Gijn
- Department of Pharmacy and Pharmacology, Slotervaart Hospital/The Netherlands Cancer Institute, Amsterdam, The Netherlands
| | - RRH Lendfers
- Department of Biomedical Analysis, Faculty of Pharmacy, Utrecht University, Utrecht, The Netherlands
| | - JHM Schellens
- Department of Biomedical Analysis, Faculty of Pharmacy, Utrecht University, Utrecht, The Netherlands, Division of Medical Oncology, The Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands
| | - A Bult
- Department of Biomedical Analysis, Faculty of Pharmacy, Utrecht University, Utrecht, The Netherlands
| | - JH Beijnen
- Department of Pharmacy and Pharmacology, Slotervaart Hospital/The Netherlands Cancer Institute, Amsterdam, The Netherlands, Department of Biomedical Analysis, Faculty of Pharmacy, Utrecht University, Utrecht, The Netherlands
| |
Collapse
|
5
|
Mokesch S, Novak MS, Roller A, Jakupec MA, Kandioller W, Keppler BK. 1,3-Dioxoindan-2-carboxamides as Bioactive Ligand Scaffolds for the Development of Novel Organometallic Anticancer Drugs. Organometallics 2015. [DOI: 10.1021/om501032s] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Affiliation(s)
- Stephan Mokesch
- Institute of Inorganic Chemistry, Faculty of Chemistry, and ‡Research
Platform “Translational Cancer Therapy Research”, University of Vienna, Waehringer Straße 42, A-1090 Vienna, Austria
| | - Maria S. Novak
- Institute of Inorganic Chemistry, Faculty of Chemistry, and ‡Research
Platform “Translational Cancer Therapy Research”, University of Vienna, Waehringer Straße 42, A-1090 Vienna, Austria
| | - Alexander Roller
- Institute of Inorganic Chemistry, Faculty of Chemistry, and ‡Research
Platform “Translational Cancer Therapy Research”, University of Vienna, Waehringer Straße 42, A-1090 Vienna, Austria
| | - Michael A. Jakupec
- Institute of Inorganic Chemistry, Faculty of Chemistry, and ‡Research
Platform “Translational Cancer Therapy Research”, University of Vienna, Waehringer Straße 42, A-1090 Vienna, Austria
| | - Wolfgang Kandioller
- Institute of Inorganic Chemistry, Faculty of Chemistry, and ‡Research
Platform “Translational Cancer Therapy Research”, University of Vienna, Waehringer Straße 42, A-1090 Vienna, Austria
| | - Bernhard K. Keppler
- Institute of Inorganic Chemistry, Faculty of Chemistry, and ‡Research
Platform “Translational Cancer Therapy Research”, University of Vienna, Waehringer Straße 42, A-1090 Vienna, Austria
| |
Collapse
|
6
|
Khaligh NG. Introduction 1,1′-butylenebis(3-methyl-3H imidazol-1-ium) Hydrogen Sulfate as an Efficient Binuclear Brönsted Acidic Ionic Liquid for Three-Component and One-Pot Synthesis of Benzo[f]indenoquinoline Derivatives. Polycycl Aromat Compd 2015. [DOI: 10.1080/10406638.2014.935448] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
7
|
Khaligh NG. Synthesis of benzo[g]indeno[2,1-b]quinoline derivatives via four-component and one-pot synthesis in presence of 3-methyl-1-sulfonic acid imidazolium hydrogen sulfate. CHINESE JOURNAL OF CATALYSIS 2014. [DOI: 10.1016/s1872-2067(14)60186-8] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
8
|
3-Methyl-1-sulfonic acid imidazolium hydrogen sulfate-catalyzed three-component, one-pot synthesis of 13-aryl-12H-benzo[f]indeno[1,2-b]quinoline-12-one derivatives. RESEARCH ON CHEMICAL INTERMEDIATES 2014. [DOI: 10.1007/s11164-014-1642-5] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
9
|
Khaligh NG. Three-component, one-pot synthesis of benzo[f]indenoquinoline derivatives catalyzed by poly(4-vinylpyridinium) hydrogen sulfate. CHINESE JOURNAL OF CATALYSIS 2014. [DOI: 10.1016/s1872-2067(12)60752-9] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
10
|
Khaligh NG, Mihankhah T. Poly(4-vinylpyridinium) hydrogen sulfate catalyzed synthesis of 12-aryl-12-hydro-5H-benzo[g]indeno[2,1-b]quinoline-6,11,13-trione derivatives. RESEARCH ON CHEMICAL INTERMEDIATES 2014. [DOI: 10.1007/s11164-014-1552-6] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
11
|
Desbois N, Pertuit D, Moretto J, Cachia C, Chauffert B, Bouyer F. cis-Dichloroplatinum(II) complexes tethered to dibenzo[c,h][1,6]naphthyridin-6-ones: Synthesis and cytotoxicity in human cancer cell lines in vitro. Eur J Med Chem 2013; 69:719-27. [DOI: 10.1016/j.ejmech.2013.09.037] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/16/2013] [Revised: 09/10/2013] [Accepted: 09/16/2013] [Indexed: 12/22/2022]
|
12
|
Yoshida M, Kabe Y, Wada T, Asai A, Handa H. A new mechanism of 6-((2-(dimethylamino)ethyl)amino)-3-hydroxy-7H-indeno(2,1-c)quinolin-7-one dihydrochloride (TAS-103) action discovered by target screening with drug-immobilized affinity beads. Mol Pharmacol 2007; 73:987-94. [PMID: 18089836 DOI: 10.1124/mol.107.043307] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
Abstract
6-((2-(Dimethylamino)ethyl)amino)-3-hydroxy-7H-indeno(2,1-c)-quinolin-7-one dihydrochloride (TAS-103) is a quinoline derivative that displays antitumor activity in murine and human tumor models. TAS-103 has been reported to be a potent topoisomerase II poison. However, other studies have indicated that cellular susceptibility to TAS-103 is not correlated with topoisomerase II expression. Because the direct target of TAS-103 remained unclear, we searched for a TAS-103 binding protein using high-performance affinity latex beads. We obtained a component of the signal recognition particle (SRP) as a TAS-103 binding protein. This component is a 54-kDa subunit (SRP54) of SRP, which mediates the proper delivery of secretory proteins in cells. We fractioned 293T cell lysates using gel-filtration chromatography and performed a coimmunoprecipitation assay using 293T cells expressing FLAG-tagged SRP54. The results revealed that TAS-103 disrupts SRP complex formation and reduces the amount of SRP14 and SRP19. TAS-103 treatment and RNAi-mediated knockdown of SRP54 or SRP14 promoted accumulation of the exogenously expressed chimeric protein interleukin-6-FLAG inside cells. In conclusion, we identified signal recognition particle as a target of TAS-103 by using affinity latex beads. This provides new insights into the mechanism underlying the effects of chemotherapies comprising TAS-103 and demonstrates the usefulness of the affinity beads.
Collapse
Affiliation(s)
- Makoto Yoshida
- Graduate School of Bioscience and Biotechnology, Tokyo Institute of Technology, 4259 Nagatsuta-cho, Midori-ku, Yokohama, Kanagawa, 226-8501, Japan
| | | | | | | | | |
Collapse
|
13
|
Shimizu K, Takada M, Asai T, Kuromi K, Baba K, Oku N. Cancer chemotherapy by liposomal 6-[12-(dimethylamino)ethyl]aminol-3-hydroxy-7H-indeno[2,1-clquinolin-7-one dihydrochloride (TAS-103), a novel anti-cancer agent. Biol Pharm Bull 2002; 25:1385-7. [PMID: 12392102 DOI: 10.1248/bpb.25.1385] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
A novel anti-tumor agent, 6-[[2-(dimethylamino)ethyl]amino]-3-hydroxy-7H-indeno[2,1-c]quinolin-7-one dihydrochloride (TAS-103), effectively inhibits both topoisomerase I and II activities. To enhance anti-tumor efficacy and to reduce the side effects of the agent, liposomalization of TAS-103 was performed. TAS-103 was effectively entrapped in liposomes by a remote-loading method, and was stable at 4 degrees C and in the presence of 50% serum. To evaluate the anti-tumor efficacy of liposomal TAS-103, the growth inhibition against Lewis lung carcinoma cells in vitro and the therapeutic efficacy against solid tumor-bearing mice in vivo were examined. Liposomal TAS-103 showed strong cytotoxic effect against Lewis lung carcinoma cells in a dose dependent manner and effectively suppressed solid tumor growth accompanying longer survival time of tumor-bearing mice in comparison with the mice treated with free TAS-103. These results suggest that liposomal TAS-103 is useful for cancer therapy.
Collapse
Affiliation(s)
- Kosuke Shimizu
- Department of Medical Biochemistry, School of Pharmaceutical Sciences, University of Shizuoka, Japan
| | | | | | | | | | | |
Collapse
|
14
|
Azuma R, Saeki M, Yamamoto Y, Hagiwara Y, Grochow LB, Donehower RC. Metabolism and urinary excretion of a new quinoline anticancer drug, TAS-103, in humans. Xenobiotica 2002; 32:63-72. [PMID: 11820510 DOI: 10.1080/00498250110085818] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/16/2022]
Abstract
1. TAS-103, a novel condensed quinoline derivative, has been developed as an anticancer drug targeting topoisomerases I and II. 2. The purpose of the present study was to characterize the metabolism and urinary excretion of TAS-103 after the intravenous infusion of a single dose to patients in Phase I clinical trials. 3. Five metabolites were detected using high-performance liquid chromatography (HPLC) photodiode array and a precursor scan by liquid chromatography mass spectrometry mass spectrometry (LC/MS/MS). 4. Structures of the five metabolites were determined using the results of enzymatic hydrolysis and the analysis of production mass spectra obtained by LC/MS/MS, and by comparing HPLC retention times and UV, mass and production mass spectra of authentic standards. 5. The metabolites were identified as demethyl-TAS-103 glucuronide (DM-TAS-103-G), TAS-103 glucuronide (TAS-103-G), TAS-103 glucuronide N-oxide (NO-TAS-103-G), demethyl-TAS-103 (DM-TAS-103) and TAS-103 N-oxide (NO-TAS-103). 6. The mean total amount of TAS-103 and TAS-103-G in urine was only 6.03% of the dose, suggesting that urine is not the main elimination route. TAS-103 was extensively metabolized, and a small percentage of the parent drug (0.41%) was found in urine.
Collapse
Affiliation(s)
- R Azuma
- Pharmacokinetics Research Laboratory, Taiho Pharmaceutical Co, Ltd, Tokushima, Japan.
| | | | | | | | | | | |
Collapse
|
15
|
Deady LW, Desneves J, Kaye AJ, Finlay GJ, Baguley BC, Denny WA. Positioning of the carboxamide side chain in 11-oxo-11H-indeno[1,2-b]quinolinecarboxamide anticancer agents: effects on cytotoxicity. Bioorg Med Chem 2001; 9:445-52. [PMID: 11249136 DOI: 10.1016/s0968-0896(00)00264-9] [Citation(s) in RCA: 49] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
A series of 11-oxo-11H-indeno[1,2-b]quinolines bearing a carboxamide-linked cationic side chain at various positions on the chromophore was studied to determine structure-activity relationships between cytotoxicity and the position of the side chain. The compounds were prepared by Pfitzinger synthesis from an appropriate isatin and 1-indanone, followed by various oxidative steps, to generate the required carboxylic acids. The 4- and 6-carboxamides (with the side chain on a terminal ring, off the short axis of the chromophore) were effective cytotoxins. The dimeric 4- and 6-linked analogues were considerably more cytotoxic than the parent monomers, but had broadly similar activities. In contrast, analogues with side chains at the 8-position (on a terminal ring but off the long axis of the chromophore) or 10-position (off the short axis of the chromophore but in a central ring) were drastically less effective. The 4,10- and 6,10-biscarboxamides had activities between those of the corresponding parent monocarboxamides. The first of these showed good activity against advanced subcutaneous colon 38 tumours in mice.
Collapse
Affiliation(s)
- L W Deady
- Department of Chemistry, La Trobe University, Bundoora, Victoria, Australia.
| | | | | | | | | | | |
Collapse
|
16
|
Zoli W, Ricotti L, Tesei A, Barzanti F, Amadori D. In vitro preclinical models for a rational design of chemotherapy combinations in human tumors. Crit Rev Oncol Hematol 2001; 37:69-82. [PMID: 11164721 DOI: 10.1016/s1040-8428(00)00110-4] [Citation(s) in RCA: 55] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/09/2023] Open
Abstract
Today, drug combinations are frequently used in the treatment of cancer to increase therapeutic efficacy. Currently used clinical protocols for cancer combination therapies are mainly obtained empirically or on the basis of results from previous clinical trials. Information obtained from clinical protocols is invaluable, but it is time-consuming, expensive and does not provide data on the biochemical and molecular mechanisms of interaction of the drugs used in combination treatments at cellular level. Therefore, in vitro drug combination studies on established cell lines or primary cell cultures play an important role in designing and optimising combination protocols. A variety of in vitro assays and different mathematics models have been developed to investigate cytotoxic effects and to analyse the type of drug interactions. Increased knowledge of the cellular targets of traditional and new drugs and the development of new technologies have resulted in a new role for the in vitro tests which are no longer used only to evaluate the cytotoxic effects of drugs, but also to investigate the interference on cell cycle, induction of apoptosis and molecular or biochemical interactions. A review on in vitro preclinical tests used to evaluate the effects of drug combinations and to design the rationale of combined chemotherapy protocols is presented.
Collapse
Affiliation(s)
- W Zoli
- Divisione di Oncologia Medica, Ospedale G.B. Morgagni-L. Pierantoni, viale Forlanini 34, 47100 Forlì, Italy.
| | | | | | | | | |
Collapse
|
17
|
Chen J, Deady LW, Desneves J, Kaye AJ, Finlay GJ, Baguley BC, Denny WA. Synthesis of substituted indeno[1,2-b]quinoline-6-carboxamides, [1]benzothieno[3,2-b]quinoline-4-carboxamides and 10H-quindoline-4-carboxamides: evaluation of structure-activity relationships for cytotoxicity. Bioorg Med Chem 2000; 8:2461-6. [PMID: 11058041 DOI: 10.1016/s0968-0896(00)00179-6] [Citation(s) in RCA: 33] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022]
Abstract
New substituted indeno[1,2-b]quinoline-6-carboxamides, [1]benzothieno[3,2-b]quinoline-4-carboxamides and 10H-quindoline-4-carboxamides were prepared from methyl 2-amino-3-formylbenzoate by a new Friedlander synthesis. Evaluation of these carboxamides for cytotoxicity in a panel of cell lines showed that small lipophilic substituents in the non-carboxamide ring, in a pseudo-peri position to the side chain, significantly increased cytotoxic potency while retaining a pattern of cytotoxicity consistent with a non-topo II mode of action. The methyl-substituted indeno[1,2-b]quinoline-6-carboxamide demonstrated substantial effectiveness (20-day growth delays) in a sub-cutaneous colon 38 in vivo tumor model. This is comparable to that reported for the dual topo I/II inhibitor DACA that is in clinical trial.
Collapse
Affiliation(s)
- J Chen
- Chemistry Department, La Trobe University, Bundoora, Victoria, Australia
| | | | | | | | | | | | | |
Collapse
|